Oculis Holding AG (OCS)
NASDAQ: OCS · Real-Time Price · USD
18.87
+1.14 (6.43%)
May 2, 2025, 4:00 PM EDT - Market closed
Oculis Holding AG Employees
Oculis Holding AG had 49 employees as of December 31, 2024. The number of employees increased by 13 or 36.11% compared to the previous year.
Employees
49
Change (1Y)
13
Growth (1Y)
36.11%
Revenue / Employee
$15,449
Profits / Employee
-$1,931,792
Market Cap
999.05M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 49 | 13 | 36.11% |
Dec 31, 2023 | 36 | 8 | 28.57% |
Dec 31, 2022 | 28 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
OCS News
- 1 day ago - Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences - GlobeNewsWire
- 1 day ago - Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences - GlobeNewsWire
- 7 days ago - Oculis Updates Share Capital - GlobeNewsWire
- 15 days ago - Oculis and EURETINA Announce the 2025 Ramin Tadayoni Award - GlobeNewsWire
- 17 days ago - Oculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets - GlobeNewsWire
- 22 days ago - Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema - GlobeNewsWire
- 22 days ago - Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema - GlobeNewsWire
- 23 days ago - Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - GlobeNewsWire